SAN FRANCISCO, CA--(Marketwired - December 10, 2015) - Sustainable harvesting the bounty of the ocean for pharmaceutical, nutritional and cosmetic uses is big business -- $186 billion per year and growing. In this interview with The Life Sciences Report, BioMarine International Clusters Association Chairman Pierre Erwes shares the names of some public and private biotech companies making waves in the blue economy.

Included in this interview is: Stellar Biotechnologies Inc. (NASDAQ: SBOT) (TSX VENTURE: KLH).

The Life Sciences Report: You are chairman of BioMarine International Clusters Association (BICA), which supports companies that harvest the resources of the sea, or what is known as the "blue economy." How large and diverse an economy are we talking about?

Pierre Erwes: In 2008 there were only 2,000 references on the Web to the "blue economy." Now, you can find more than 20 million references, so it is growing exponentially. The biomarine industry represented $186 billion ($186B) alone last year. Unfortunately, this industry is still structured in silos, and the blue complement lacks visibility.

Marine biotech represents 8% of the total of the biotech market, and biomaterials account for less than 1% of the total market. Bioenergy is 2% of the energy market. Blue chemistry, which is one of the largest segments, is producing only 6% of the total chemical product globally. Marine compounds represent 13% of the cosmetic market right now. Aquaculture has made the most…

Continue reading this interview: How to Get Your Piece of the Growing $186B Biomarine Industry: BICA's Pierre Erwes

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.

DISCLOSURE:

Stellar Biotechnologies Inc. is a banner sponsor of Streetwise Reports. Pierre Erwes had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Mr. Erwes and not of The Life Sciences Report or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.